Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
F 131.79 5.48% 6.85
ASND closed down 0.07 percent on Wednesday, April 21, 2021, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical ASND trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 5.99%
Slingshot Bearish Bearish Swing Setup 5.91%
MACD Bullish Signal Line Cross Bullish 5.91%
Oversold Stochastic Weakness 5.91%
New 52 Week Closing Low Bearish 8.88%
Lizard Bullish Bullish Day Trade Setup 8.88%
NR7 Range Contraction 8.88%
Doji - Bullish? Reversal 8.88%
New 52 Week Low Weakness 8.88%
Multiple of Ten Bullish Other 8.88%
Older End-of-Day Signals for ASND ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Upper Bollinger Band Resistance about 3 hours ago
Rose Above Upper Bollinger Band about 3 hours ago
10 DMA Support about 3 hours ago
Up 5% about 3 hours ago
Up 3% about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ascendis Pharma A/S Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Pulmonary Arterial Hypertension Breakthrough Therapy Peptide Hormones Growth Hormone Treatment Of Diabetes Drug Therapies Recombinant Proteins Growth Hormone Deficiency Growth Hormone Therapy Prodrug Treprostinil United Therapeutics

Is ASND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 183.98
52 Week Low 119.29
Average Volume 221,812
200-Day Moving Average 151.84
50-Day Moving Average 141.35
20-Day Moving Average 127.16
10-Day Moving Average 124.53
Average True Range 4.83
ADX 37.33
+DI 14.40
-DI 26.14
Chandelier Exit (Long, 3 ATRs ) 131.07
Chandelier Exit (Short, 3 ATRs ) 133.78
Upper Bollinger Band 133.80
Lower Bollinger Band 120.52
Percent B (%b) 0.33
BandWidth 10.44
MACD Line -5.07
MACD Signal Line -5.52
MACD Histogram 0.4504
Fundamentals Value
Market Cap 6.67 Billion
Num Shares 53.4 Million
EPS -5.09
Price-to-Earnings (P/E) Ratio -24.52
Price-to-Sales 753.04
Price-to-Book 7.67
PEG Ratio -0.27
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 128.75
Resistance 3 (R3) 128.55 127.08 128.12
Resistance 2 (R2) 127.08 126.11 127.18 127.90
Resistance 1 (R1) 126.01 125.51 126.55 126.21 127.69
Pivot Point 124.54 124.54 124.81 124.64 124.54
Support 1 (S1) 123.47 123.57 124.01 123.67 122.19
Support 2 (S2) 122.00 122.97 122.10 121.98
Support 3 (S3) 120.93 122.00 121.77
Support 4 (S4) 121.13